Citations

Clear

3942 citation(s) found for "To, Van".

Coordination of Centrosome Homeostasis and DNA Repair Is Intact in MCF-7 and Disrupted in MDA-MB 231 Breast Cancer Cells
Acu, Ilie D., Liu, Tieju , Suino-Powell, Kelly, Mooney, Steven M. , D’Assoro, Antonino B. , Correa, Ricardo G. , Niu, Yun , Kumar, Rajiv , Salisbury, Jeffrey L., Rowland, Nicholas James , Muotri, Alysson Renato , Kumar, Rajiv

Mayo Clinic

Cancer Research | April 13, 2010 | Volume: 70 | Issue: 8 | Pages: 3320-3328

10.1158/0008-5472.can-09-3800 | PMID 20388771 Get It

Abstract When cells encounter substantial DNA damage, critical cell cycle events are halted while DNA repair mechanisms are activated to restore genome integrity. Genomic integrity also depends on proper assembly and function of the bipolar mitotic spindle, which is required for equal chromosome segregation. Failure to execute either of these processes leads to genomic instability, aging, and cancer. Here, we show that following DNA damage in the breast cancer cell line MCF-7, the centrosome protein centrin2 moves from the cytoplasm and accumulates in the nucleus in a xeroderma pigmentosum complementation group C protein (XPC)–dependent manner, reducing the available cytoplasmic pool of this key centriole protein and preventing centrosome amplification. MDA-MB 231 cells do not express XPC and fail to move centrin into the nucleus following DNA damage. Reintroduction of XPC expression in MDA-MB 231 cells rescues nuclear centrin2 sequestration and reestablishes control against centrosome amplification, regardless of mutant p53 status. Importantly, the capacity to repair DNA damage was also dependent on the availability of centrin2 in the nucleus. These observations show that centrin and XPC cooperate in a reciprocal mechanism to coordinate centrosome homeostasis and DNA repair and suggest that this process may provide a tractable target to develop treatments to slow progression of cancer and aging. Cancer Res; 70(8); 3320–8. ©2010 AACR.
Magnetic resonance imaging–graded hypothalamic compression in surgically treated adult craniopharyngiomas determining postoperative obesity
Nippoldt, Todd B., Higgins, Dominique , Meyer, Fredric B. , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | April 1, 2010 | Volume: 28 | Issue: 4 | Pages: E3

10.3171/2010.1.focus09303 | PMID 20367360 Get It

Object Obesity as a consequence of management of pediatric craniopharyngioma is a well-described phenomenon related to the degree of hypothalamic involvement. However, weight change and obesity have not been analyzed in adult patients. Therefore, the purpose of this study was 1) to evaluate the pattern of postoperative weight gain related to preoperative body mass index (BMI), 2) determine if postoperative weight gain is an issue in adult patients, and 3) develop an objective MR imaging grading system to predict risk of postoperative weight gain and obesity in adults treated for craniopharyngioma. Methods The authors retrospectively screened 296 patients with known craniopharyngioma for the following inclusion criteria: pathologically confirmed craniopharyngioma, index surgery at the authors' institution, and operative weight and height recorded with at least 3 months of follow-up including body weight measurement. Patients aged 18 years or younger were excluded, yielding 28 cases for analysis. Cases of craniopharyngiomas were compared with age- and sex-matched controls (pituitary adenoma patients) to evaluate the pattern and significance of perioperative weight changes. Results Mean age was 46 ± 17 years at surgery, and 64% of the patients were male. Complete resection was achieved in 71% of cases. There was no correlation of preoperative BMI and postoperative weight gain testing in a linear model. Sixty-one percent and 46% of patients had postoperative weight gains greater than 4 and 9%, respectively. Comparing craniopharyngioma patients (cases) to age- and sex-matched controls, the preoperative BMIs were similar (p = 0.93) between cases (mean 28.9 [95% CI 30.9–26.9]) and controls (mean 29.3 [95% CI 31.9–26.7]). However, there was a trend to a greater mean postoperative weight change (percentage) in cases (10.1%) than in controls (5.6%) (p = 0.24). Hypothalamic T2 signal change and irregular contrast enhancement correlated and predicted higher-grade hypothalamic involvement. Furthermore, they can be used to objectively grade hypothalamic involvement as the authors propose. Progressive hypothalamic involvement correlated with larger postoperative weight gains (p = 0.022); however, hypothalamic involvement did not correlate with preoperative BMI (p = 0.5). Conclusions Postoperative weight gain in adult patients undergoing surgery for craniopharyngioma is a significant problem and correlates with hypothalamic involvement, as it does in pediatric patients. Finally, objective MR imaging criteria can be used to predict risk of postoperative weight gain and aid in grading of hypothalamic involvement.
Advanced Heart Failure and Nocturnal Hypoxaemia Due to Central Sleep Apnoea are Associated with Increased Serum Erythropoietin
Calvin, Andrew D. , Steensma, David P. , Pérez, José A., Walt, Christelle van der, Fitz‐Gibbon, Jennifer M., Scott, Christopher G. , Olson, Lyle J. , Somers, Virend K. , Scott, Christopher , Steensma, David P , Calvin, Andrew D

Mayo Clinic

European Journal of Heart Failure | March 24, 2010 | Volume: 12 | Issue: 4 | Pages: 354-359

10.1093/eurjhf/hfq005 | PMID 20335353 Get It

Abstract Aims Central sleep apnoea (CSA) and increased serum erythropoietin (EPO) concentration have each been associated with adverse prognosis in heart failure (HF) patients. The aim of this study was to examine the relationship between nocturnal hypoxaemia due to CSA and the serum EPO concentration in patients with HF. Methods and results Heart failure subjects (n = 33) and healthy controls (n = 18) underwent polysomnography (PSG) for diagnosis of CSA and identification and quantification of hypoxaemia. Blood collection for measurement of EPO was performed immediately post-PSG. For the analysis, HF subjects were dichotomized into subgroups defined by the presence or absence of CSA and by HF severity. Multivariate analyses were performed to evaluate the relationships of hypoxaemia and advanced HF to EPO concentration. Mean EPO concentration was 62% higher for HF subjects with CSA than for healthy controls (P = 0.004). The magnitude of nocturnal hypoxaemia was significantly and positively related to EPO concentration (r = 0.45, P = 0.02). Advanced HF was also significantly and positively related to EPO concentration (r = 0.43, P = 0.02). On multivariate analysis, the presence of combined nocturnal hypoxaemia and advanced HF yielded greater correlation to EPO concentration than either factor alone (r = 0.57, P = 0.04 and P = 0.05, respectively). Linear regression demonstrated that the combination of New York Heart Association Class and CSA was strongly associated with EPO concentration (P < 0.0001). Conclusion In non-anaemic HF patients, advanced HF and hypoxaemia due to CSA may each be independently associated with increased serum EPO concentration.
Stereotactic electroencephalography with temporal grid and mesial temporal depth electrode coverage: does technique of depth electrode placement affect outcome?
Meyer, Fredric B. , Marsh, W. Richard , Lee, Kendall H. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Journal of Neurosurgery | February 19, 2010 | Volume: 113 | Issue: 1 | Pages: 32-38

10.3171/2009.12.jns091073 | PMID 20170311 Get It

Object Intracranial monitoring for temporal lobe seizure localization to differentiate neocortical from mesial temporal onset seizures requires both neocortical subdural grids and hippocampal depth electrode implantation. There are 2 basic techniques for hippocampal depth electrode implantation. This first technique uses a stereotactically guided 8-contact depth electrode directed along the long axis of the hippocampus to the amygdala via an occipital bur hole. The second technique involves direct placement of 2 or 3 4-contact depth electrodes perpendicular to the temporal lobe through the middle temporal gyrus and overlying subdural grid. The purpose of this study was to determine whether one technique was superior to the other by examining monitoring success and complications. Methods Between 1997 and 2005, 41 patients underwent invasive seizure monitoring with both temporal subdural grids and depth electrodes placed in 2 ways. Patients in Group A underwent the first technique, and patients in Group B underwent the second technique. Results Group A consisted of 26 patients and Group B 15 patients. There were no statistically significant differences between Groups A and B regarding demographics, monitoring duration, seizure localization, or outcome (Engel classification). There was a statistically significant difference at the point in time at which these techniques were used: Group A represented more patients earlier in the series than Group B (p < 0.05). The complication rate attributable to the grids and depth electrodes was 0% in each group. It was more likely that the depth electrodes were placed through the grid if there was a prior resection and the patient was undergoing a new evaluation (p < 0.05). Furthermore, Group A procedures took significantly longer than Group B procedures. Conclusions In this patient series, there was no difference in efficacy of monitoring, complications, or outcome between hippocampal depth electrodes placed laterally through temporal grids or using an occipital bur hole stereotactic approach. Placement of the depth electrodes perpendicularly through the grids and middle temporal gyrus is technically more practical because multiple head positions and redraping are unnecessary, resulting in shorter operative times with comparable results.
Polymorphism in the GALNT1 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium
Phelan, Catherine M., Tsai, Ya-Yu, Goode, Ellen L. , Vierkant, Robert A. , Beesley, Jonathan, Chen, Xiao Qing, Webb, Penelope M. , Moysich, Kirsten B., Edwards, Robert P., Chang‐Claude, Jenny , García‐Closas, Montserrat , Wang‐Gohrke, Shan , Hein, Rebecca, Lissowska, Jolanta , Carney, Michael E., Lurie, Galina, Ness, Roberta B., Pearce, Celeste Leigh, Wu, Anna H. , Berg, David J. Van Den, Terry, Kathryn L. , Whiteman, David C. , Whittemore, Alice S. , DiCioccio, Richard A., McGuire, Valerie , Rossing, Mary Anne, Høgdall, Claus , Høgdall, Estrid , Kjær, Susanne K. , Blaakær, Jan , Quaye, Lydia, Ramus, Susan J. , Jacobs, Ian , Song, Honglin , Iversen, Edwin S., Marks, Jeffrey R. , Pike, Malcolm C. , Gayther, Simon A. , Cunningham, Julie M. , Goodman, Marc T. , Schildkraut, Joellen M. , Chenevix‐Trench, Georgia , Sellers, Thomas A. , Group, Australian Ovarian Cancer Study, Fridley, Brooke L. , Chen, Xiao Qing, Chanock, Stephen Jacob , Cramer, Daniel W. , Yang, Hannah , Green, Adèle C. , Wilkens, Lynne R. , Stram, Daniel O. , Doherty, Jennifer A. , Anton‐Culver, Hoda , Ziogas, Argyrios , Pharoah, Paul D.P. , Berchuck, Andrew , Group, Australian Ovarian Cancer Study, Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Whiteman, David C , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 8, 2010 | Volume: 19 | Issue: 2 | Pages: 600-604

10.1158/1055-9965.epi-09-0861 | PMID 20142253 Get It

Abstract Aberrant glycosylation is a well-described hallmark of cancer. In a previous ovarian cancer case control study that examined polymorphisms in 26 glycosylation-associated genes, we found strong statistical evidence (P = 0.00017) that women who inherited two copies of a single-nucleotide polymorphism in the UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase, GALNT1, had decreased ovarian cancer risk. The current study attempted to replicate this observation. The GALNT1 single-nucleotide polymorphism rs17647532 was genotyped in 6,965 cases and 8,377 controls from 14 studies forming the Ovarian Cancer Association Consortium. The fixed effects estimate per rs17647532 allele was null (odds ratio, 0.99; 95% confidence interval, 0.92-1.07). When a recessive model was fit, the results were unchanged. Test for hetero geneity of the odds ratios revealed consistency across the 14 replication sites but significant differences compared with the original study population (P = 0.03). This study underscores the need for replication of putative findings in genetic association studies. Cancer Epidemiol Biomarkers Prev; 19(2); 600–4
Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation
Ree, Janine H. van, Jeganathan, Karthik B. , Malureanu, Liviu, Deursen, Jan M. van , Jeganathan, Karthik B

Mayo Clinic

Journal of Cell Biology | January 11, 2010 | Volume: 188 | Issue: 1 | Pages: 83-100

10.1083/jcb.200906147 | PMID 20065091 Get It

The anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase functions with the E2 ubiquitin–conjugating enzyme UbcH10 in the orderly progression through mitosis by marking key mitotic regulators for destruction by the 26-S proteasome. UbcH10 is overexpressed in many human cancer types and is associated with tumor progression. However, whether UbcH10 overexpression causes tumor formation is unknown. To address this central question and to define the molecular and cellular consequences of UbcH10 overexpression, we generated a series of transgenic mice in which UbcH10 was overexpressed in graded fashion. In this study, we show that UbcH10 overexpression leads to precocious degradation of cyclin B by the APC/C, supernumerary centrioles, lagging chromosomes, and aneuploidy. Importantly, we find that UbcH10 transgenic mice are prone to carcinogen-induced lung tumors and a broad spectrum of spontaneous tumors. Our results identify UbcH10 as a prominent protooncogene that causes whole chromosome instability and tumor formation over a wide gradient of overexpression levels.
ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study
Rossing, Mary Anne, Cushing‐Haugen, Kara L. , Chen, Chu , Berg, David J. Van Den, Wu, Anna H. , Pike, Malcolm C. , Ness, Roberta B., Moysich, Kirsten B., Chenevix‐Trench, Georgia , Beesley, Jonathan, Webb, Penelope M. , Chang‐Claude, Jenny, Wang‐Gohrke, Shan , Goodman, Marc T. , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Høgdall, Estrid , Kjær, Susanne K. , Høgdall, Claus , Goode, Ellen L. , Cunningham, Julie M. , Vierkant, Robert A. , Moorman, Patricia G. , Schildkraut, Joellen M. , Palmieri, Rachel T., Terry, Kathryn L. , García‐Closas, Montserrat , Lissowska, Jolanta , Song, Honglin , Shah, Mitul , Perkins, Barbara, McGuire, Valerie , Whittemore, Alice S. , Cioccio, Richard A. Di, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Group, The Australian Ovarian Cancer Study Management, Cancer), The Australian Cancer Study (Ovarian, Pearce, Celeste Leigh, Weber, Rachel Palmieri , Doherty, Jennifer A. , Fridley, Brooke L. , Berchuck, Andrew , Cramer, Daniel W. , Yang, Hannah , Chanock, Stephen Jacob , Pharoah, Paul D.P. , Gentry‐Maharaj, Aleksandra , Ziogas, Argyrios , Brewster, Wendy R. , Anton‐Culver, Hoda , Group, The Australian Ovarian Cancer Study Management, Cancer), The Australian Cancer Study (Ovarian, Pearce, Celeste Leigh, Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 7, 2010 | Volume: 19 | Issue: 1 | Pages: 245-250

10.1158/1055-9965.epi-09-0729 | PMID 20056644 Get It

Abstract We genotyped 13 single nucleotide polymorphisms (SNPs) in the estrogen receptor alpha gene (ESR1) region in three population-based case-control studies of epithelial ovarian cancer conducted in the United States, comprising a total of 1,128 and 1,866 non-Hispanic white invasive cases and controls, respectively. A SNP 19 kb downstream of ESR1 (rs2295190, G-to-T change) was associated with invasive ovarian cancer risk, with a per-T-allele odds ratio (OR) of 1.24 [95% confidence interval (CI), 1.06-1.44, P = 0.006]. rs2295190 is a nonsynonymous coding SNP in a neighboring gene called spectrin repeat containing, nuclear envelope 1 (SYNE1), which is involved in nuclear organization and structural integrity, function of the Golgi apparatus, and cytokinesis. An isoform encoded by SYNE1 has been reported to be downregulated in ovarian and other cancers. rs2295190 was genotyped in an additional 12 studies through the Ovarian Cancer Association Consortium, with 5,279 invasive epithelial cases and 7,450 controls. The per-T-allele OR for this 12-study set was 1.09 (95% CI, 1.02-1.17; P = 0.017). Results for the serous subtype in the 15 combined studies were similar to those overall (n = 3,545; OR, 1.09; 95% CI, 1.01-1.18; P = 0.025), and our findings were strongest for the mucinous subtype (n = 447; OR, 1.32; 95% CI, 1.11-1.58; P = 0.002). No association was observed for the endometrioid subtype. In an additional analysis of 1,459 borderline ovarian cancer cases and 7,370 controls, rs2295190 was not associated with risk. These data provide suggestive evidence that the rs2295190 T allele, or another allele in linkage disequilibrium with it, may be associated with increased risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev; 19(1); 244–50
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
Yao, James C. , Baudin, Éric , Kvols, Larry K., Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, Peter, J., Haas, T , Lebwohl, David , Kulke, Matthew H. , Hobday, Timothy J. , O’Dorisio, Thomas M. , Shah, Manisha H. , Cadiot, Guillaume , Luppi, Gabriele , Posey, James , Wiedenmann, Bertram , Lombard‐Bohas, Catherine , Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | November 23, 2009 | Volume: 28 | Issue: 1 | Pages: 69-76

10.1200/jco.2009.24.2669 | PMID 19933912 Get It

Purpose No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. Patients and Methods This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months. Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline. Trough concentrations of everolimus and octreotide were assessed. Results By central radiology review, in stratum 1, there were 11 partial responses (9.6%), 78 patients (67.8%) with stable disease (SD), and 16 patients (13.9%) with progressive disease; median progression-free survival (PFS) was 9.7 months. In stratum 2, there were two partial responses (4.4%), 36 patients (80%) with SD, and no patients with progressive disease; median PFS was 16.7 months. Patients with an early CgA or NSE response had a longer PFS compared with patients without an early response. Coadministration of octreotide LAR and everolimus did not impact exposure to either drug. Most adverse events were mild to moderate and were consistent with those previously seen with everolimus. Conclusion Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy.
International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis
Hussein, Kebede, Pardanani, Animesh , Dyke, Daniel L. Van , Hanson, Curtis A. , Tefferi, Ayalew

Mayo Clinic

Blood | November 10, 2009 | Volume: 115 | Issue: 3 | Pages: 496-499

10.1182/blood-2009-08-240135 | PMID 19901264 Get It

Abstract Among 200 patients with primary myelofibrosis, karyotype at diagnosis was abnormal in 83 (42%). To assess their individual prognostic impact, specific cytogenetic abnormalities with more than or equal to 5 informative cases were identified and the rest grouped separately as “other abnormalities.” Median survival in patients with sole +9 (n = 6), sole 20q− (n = 21), sole 13q− (n = 8), normal karyotype (n = 117), “other abnormalities” (n = 28), complex karyotype (n = 13), and sole +8 (n = 7) were “not reached,” 112, 105, 80, 46, 34, and 28 months, respectively (P = .01). Accordingly, 4 cytogenetic risk groups were considered: (1) favorable (sole +9, 20q−, or 13q−), (2) normal, (3) unfavorable (complex karyotype or sole +8), and (4) “other abnormalities.” Multivariable analysis confirmed the International Prognostic Scoring System (IPSS)–independent prognostic value of both 4-way and 2-way (ie, favorable/normal vs unfavorable/other abnormalities; IPSS-adjusted hazard ratio = 0.37; 95% confidence interval, 0.24-0.58) cytogenetic risk categorization (P < .01). The ability to prognostically dissect a specific IPSS category has major therapeutic implications.